51598-76-6

Usage

Uses

Used in Pharmaceutical Research:
6-METHYLNICOTINOYL CHLORIDE is used as a building block for the production of various drugs and biologically active molecules, playing a crucial role in the creation of new chemical entities.
Used in Organic Synthesis:
6-METHYLNICOTINOYL CHLORIDE is used as a reagent in organic synthesis, particularly for its reactivity in acylation and amidation reactions.
Used in Development of Pharmaceuticals:
6-METHYLNICOTINOYL CHLORIDE is used as a key component in the development of pharmaceuticals, contributing to the discovery and synthesis of new therapeutic agents.
Used in Development of Agrochemicals:
6-METHYLNICOTINOYL CHLORIDE is also used in the development of agrochemicals, where its reactivity and properties are employed to create new compounds for agricultural applications.
It is important to handle 6-METHYLNICOTINOYL CHLORIDE with care in a controlled laboratory environment due to its potentially hazardous properties.

Upstream product

• 3222-47-7 6-methylnicotinic acid 

Downstream Products

• 5470-70-2 Methyl 6-methylnicotinate 
• 1076692-17-5 6-methyl-4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl] nicotinanilide monohydrochloride 
• 1333404-75-3 tert-butyl N-[3-[1-(3-benzyl-4-oxothieno[3,2-d]pyrimidin-2-yl)propyl-(6-methylpyridine-3-carbonyl)amino]propyl]carbamate 
• 40337-65-3 2-bromo-1-(6-methylpyridin-3-yl)ethan-1-one 
• 1448612-16-5 2-[1-(4-bromophenyl)cyclobutyl]-4-(6-methyl-3-pyridyl)thiazole 
• 1211583-88-8 2-fluoro-6-methylpyridine-3-carboxylic acid 
• 221615-72-1 1-(6-methyl-3-pyridinyl)-2-[4-(methyl sulfide)phenyl]ethanone 
• 676533-42-9 6-methyl-N-(2-methylcyclohexyl)nicotinamide 
• 676533-43-0 6-methyl-N-(4-methylcyclohexyl)nicotinamide 
• 36357-38-7 1-(6-methyl-pyridin-3-yl)-ethanone 
• 732245-99-7 5-isocyanato-2-methylpyridine 

Relevant academic research and scientific papers

Catalytic Deoxygenative Coupling of Aromatic Esters with Organophosphorus Compounds

We have developed a deoxygenative coupling of aromatic esters with diarylphosphine oxides/dialkyl phosphonates under palladium catalysis. In this reaction, aromatic esters can work as novel benzylation reagents to give the corresponding benzylic phosphorus compounds. The key of this reaction is the use of phenyl esters, an electron-rich diphosphine as a ligand, and sodium formate as a hydrogen source. Arylcarboxylic acids were also applicable in this reaction using (Boc)2O as an additive. Palladium/dcype worked to activate the acyl C-O bond of the ester and to support the reduction with sodium formate.

NOVEL NUCLEOSIDE OR NUCLEOTIDE DERIVATIVES, AND USES THEREOF

The present disclosure relates to a novel nucleoside or nucleotide derivative, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating viral infection-associated diseases, containing the same as an active ingredient.

Nickel-Catalyzed Oxidative Decarboxylative Annulation for the Synthesis of Heterocycle-Containing Phenanthridinones

A nickel-catalyzed oxidative decarboxylative annulation reaction of simple benzamides and (hetero)aromatic carboxylates has been developed. This reaction provides access to a large array of phenanthridinones and their heterocyclic analogues, highlighting the utility and versatility of oxidative decarboxylative coupling strategies for C-C bond formation.

NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS

The present application relates to nitrogen-containing fused ring compounds shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof as CRTH2 antagonist, wherein X1, X2, X3, X4, X5, W, X, Y, L1, L2, L3, A, B are as defined in the description; the present application further relates to a method for preparing the compounds, a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, a use of the compounds for the manufacture of a medicament for the treatment and/or prevention of diseases related to activity of CRTH2.

NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS

The present application relates to nitrogen-containing fused ring compounds shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof as CRTH2 antagonist, wherein X1, X2, X3, X4, X5, W, X, Y, L1, L2, L3, A, B are as defined in the description; the present application further relates to a method for preparing the compounds, a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, a use of the compounds for the manufacture of a medicament for the treatment and/or prevention of diseases related to activity of CRTH2.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION

The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R7, A and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes

Rh(III)-catalyzed C-H activation and double directing group strategy for the regioselective synthesis of naphthyridinones

A general Rh(III)-catalyzed synthesis of naphthyridinone derivatives is described. It relies on a double-activation and directing approach leveraging nicotinamide N-oxides as substrates. In general, high yields and selectivities can be achieved using low

Synthesis, biological evaluation and molecular docking studies of 1,3,4-thiadiazole derivatives containing 1,4-benzodioxan as potential antitumor agents

A series of 1,3,4-thiadiazole derivatives containing 1,4-benzodioxan (2a-2s) have been synthesized to screen for FAK inhibitory activity. Compound 2p showed the most potent biological activity against HEPG2 cancer cell line (EC50 = 10.28 μg/mL

AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS

The invention relates to compounds of formula (I), wherein R, R1, m, n and X1to X3 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention

Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors

The invention provides a compound of formula (I) or a salt thereof: wherein R2 is H, C1-3alkyl, n-butyl, C1-2fluoroalkyl, cyclopropyl, cyclobutyl, (cyclopropyl)methyl-, —CN, or —CH2OH; R3 is inter alia optionally substituted C4-7cycloalkyl or an optionally substituted heterocyclic group (aa), (bb) or (cc); Ra is H, methyl or ethyl; Rb is H or methyl; R4 is H, methyl, ethyl, n-propyl, —C(O)-Me, or —C(O)—C1fluoroalkyl; and R5 is: —C(O)—(CH2)n—Ar, —C(O)-Het, —C(O)—C1-6alkyl, —C(O)—C1 fluoroalkyl, —C(O)—(CH2)2—C(O)—NR15bNR15b, —C(O)—CH2—C(O)—NR15bNR15b, —C(O)—NR15b—(CH2)m1—Ar, —C(O)—NR15b—Het, —C(O)—NR15b—C1-6alkyl, —C(O)—NR5aR5b, —S(O)2—(CH2)m2—Ar, —S(O)2-Het, —S(O)2—C1-6alkyl, or —CH2—Ar; or R4 and R5 taken together are —(CH2)p1—, —(CH2)2—X5—(CH2)2—, —C(O)—(CH2)p2—, —C(O)—N(R15)—(CH2)p3—; or NR4R5 is of sub-formula (y), (y1), (y2) or (y3). The invention provides the use of the compounds as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as COPD and the like.